

VYVGART[®]
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

VYVGART[®] Hytrulo
(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

VYVGART for IV infusion and VYVGART Hytrulo for subcutaneous injection are both FDA-approved treatments for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG)

AChR=acetylcholine receptor; IV=intravenous
Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

Doctor Discussion Guide

Start the conversation about your anti-AChR antibody positive gMG symptoms and daily abilities

- ➔ **Fill out and bring** this guide with you to your next appointment with your neurologist
- ➔ **Discuss** your current **anti-AChR antibody positive gMG symptoms** and how they impact your **daily abilities** with your doctor
- ➔ **Ask** your neurologist if VYVGART for IV infusion or VYVGART Hytrulo for subcutaneous injection could be right for you

What is VYVGART[®] (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART[®] HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

Choose the VYVGART option that is best for you

VYVGART[®]
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

For **IV infusion**—given by inserting a needle into a vein so the medicine enters the bloodstream.

VYVGART is a **1-hour IV infusion** given at an infusion center, neurologist's office, or at home.*

VYVGART[®] Hytrulo
(efgartigimod alfa and
hyaluronidase-qvfc)
Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

For **subcutaneous injection**—given by delivering medicine into the layer beneath the skin.

VYVGART Hytrulo usually takes **30 to 90 seconds to inject** and is given at an infusion center, doctor's office, or at home.†‡

*In some cases, VYVGART for IV infusion may also be administered at home by a trained nurse.

†For at least 30 minutes after your injection, a healthcare professional will monitor you for reactions.

‡In some cases, VYVGART Hytrulo may also be given at home by a trained nurse.

IV=intravenous

Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

SELECT IMPORTANT SAFETY INFORMATION

More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART or VYVGART HYTRULO.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

YOUR CURRENT TREATMENT PLAN

- 1 Does your current treatment plan do enough to help you perform daily activities?
 Yes No
- 2 Are you interested in talking to your doctor about whether VYVGART could be right for you?
 Yes No
- 3 Take a moment to track your recent symptoms using the MG-ADL scale on the next page and total up your score. Is this level of symptom control acceptable to you?
 Yes No

You can use this space to write down anything else you'd like to talk to your doctor about, including questions about your symptoms.



Could VYVGART be right for you?

Learn more at [VYVGART.com](https://www.vyvgart.com)

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider right away if you have signs or symptoms of an infection during treatment with VYVGART or VYVGART HYTRULO such as fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

YOUR ANTI-AChR ANTIBODY POSITIVE GENERALIZED MYASTHENIA GRAVIS (gMG) SYMPTOMS

The **Myasthenia Gravis Activities of Daily Living (MG-ADL)** scale assesses the impact of gMG on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

Grade	0	1	2	3	Score (0, 1, 2, or 3)
1. Talking	Normal	Intermittent slurring or nasal speech	Constant slurring or nasal, but can be understood	Difficult to understand speech	+
2. Chewing	Normal	Fatigue with solid food	Fatigue with soft food	Gastric tube	+
3. Swallowing	Normal	Rare episode of choking	Frequent choking necessitating changes in diet	Gastric tube	+
4. Breathing	Normal	Shortness of breath with exertion	Shortness of breath at rest	Ventilator dependence	+
5. Impairment of ability to brush teeth or comb hair	None	Extra effort, but no rest periods needed	Rest periods needed	Cannot do one of these functions	+
6. Impairment of ability to arise from a chair	None	Mild, sometimes uses arms	Moderate, always uses arms	Severe, requires assistance	+
7. Double vision	None	Occurs, but not daily	Daily, but not constant	Constant	+
8. Eyelid droop	None	Occurs, but not daily	Daily, but not constant	Constant	+

MG-ADL score total (Add lines 1-8) =

This information has been provided for educational purposes only and is not meant to be a substitute for professional medical advice. Patients should not use this information for diagnosing a health condition. Patients should always consult a healthcare professional for medical advice or information about diagnosis and treatment.

Source: Wolfe GI, et al. *Neurology*. 1999;52(7):1487-1489.



You can use the space below to describe your anti-AChR antibody positive gMG symptoms and how they impact your daily abilities

1. Talking	
2. Chewing	
3. Swallowing	
4. Breathing	
5. Impairment of ability to brush teeth or comb hair	
6. Impairment of ability to arise from a chair	
7. Double vision	
8. Eyelid droop	

In addition to the severity of your anti-AChR antibody positive gMG symptoms and how they impact your daily abilities, your neurologist may also ask you how frequently you experience each anti-AChR antibody positive gMG symptom.

When added to their current gMG treatment, VYVGART helped patients in the study with anti-AChR antibody positive gMG achieve:

Improved daily abilities

68% (44 of 65) of patients on VYVGART achieved significant improvement in their ability to perform daily activities*

Compared to 30% (19 of 64) of patients on placebo plus current treatment

Reduced muscle weakness

63% (41 of 65) of patients on VYVGART achieved a significant reduction in muscle weakness†

Compared to 14% (9 of 64) of patients on placebo plus current treatment

VYVGART was evaluated in a global study of adults with anti-AChR antibody positive gMG.

The study examined the safety and effectiveness of VYVGART in 167 adults (18 years or older‡) with gMG. In addition to their current treatment, patients received either VYVGART or placebo.

*Improvement maintained for 4 or more weeks was measured by a decrease of 2 or more points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, with the first reduction occurring no later than 1 week after the last infusion of treatment cycle 1. The MG-ADL scale assesses the impact of gMG on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

†Improvement maintained for 4 or more weeks was measured by a decrease of 3 or more points on the Quantitative Myasthenia Gravis (QMG) scale, with the first reduction occurring no later than 1 week after the last infusion of treatment cycle 1. The QMG scale assesses muscle weakness in gMG based on 13 items. Each item is assessed on a 4-point scale, where a score of 0 represents no muscle weakness and a score of 3 represents severe muscle weakness. Total scores range from 0 to 39, with a higher score meaning muscle weakness is more severe.

‡Patients in Japan were 20 years or older.


SELECT IMPORTANT SAFETY INFORMATION

The most common side effects of efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).

VYVGART was safe in treating most patients in the study and has a proven safety profile

In the study, the following side effects were reported in at least 5% of patients on VYVGART and more frequently than in patients on placebo



Most infections in patients on VYVGART were mild to moderate. Additionally, more patients on VYVGART vs. placebo had lower white blood cell counts that were mild to moderate in severity.

Hypersensitivity reactions including rash, swelling under the skin, and shortness of breath were observed in some VYVGART-treated patients.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis

Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

VYVGART Hytrulo was found to be effective for adults with anti-AChR antibody positive gMG

The effectiveness of VYVGART Hytrulo was established through 2 studies.

In the VYVGART Hytrulo study, VYVGART Hytrulo for subcutaneous injection had a similar reduction in the harmful AChR antibodies that cause gMG symptoms as VYVGART for IV infusion.

In the VYVGART for IV infusion study, a reduction in harmful AChR antibodies was associated with improved daily abilities (reduction in total MG-ADL score).

See page 6 for study results.

VYVGART Hytrulo study design: The study compared antibody reduction in 110 adults (18 years or older) with gMG who remained on their current gMG treatment and were given either VYVGART Hytrulo for subcutaneous injection or VYVGART for IV infusion.



SELECT IMPORTANT SAFETY INFORMATION

The most common side effects of efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).



VYVGART Hytrulo was safe in treating most patients studied

The safety of VYVGART Hytrulo was established through 2 studies.

The overall safety of VYVGART Hytrulo for subcutaneous injection was consistent with the safety profile of VYVGART for IV infusion, except patients on VYVGART Hytrulo for subcutaneous injection experienced more injection site reactions.

In the VYVGART for IV infusion study, the most common side effects for VYVGART for IV infusion-treated patients were respiratory tract infection, headache, and urinary tract infection. Additionally, more patients on VYVGART for IV infusion vs. placebo had lower white blood cell counts that were mild to moderate in severity.

See page 7 for study results.

In the VYVGART Hytrulo study, the most common side effects of VYVGART Hytrulo-treated patients were injection site reactions, 38% (21 of 55), and headache. Injection site reactions included injection site rash, redness of the skin, itching sensation, bruising, pain, and hives.

In the VYVGART Hytrulo study and its long-term safety study:

- ➔ All injection site reactions were mild to moderate and didn't lead to treatment discontinuation
- ➔ The majority of injection site reactions occurred within 24 hours of injection and resolved on their own
- ➔ The majority of injection site reactions occurred during the first treatment cycle and decreased with each subsequent cycle

Hypersensitivity reactions including rash, swelling under the skin, shortness of breath, and hives were observed in some VYVGART Hytrulo-treated patients.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IV=intravenous

Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

- **Infection.** VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. More patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts. The majority of infections and observed lower white blood cell counts were mild to moderate in severity. Your healthcare provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART or VYVGART HYTRULO. Tell your healthcare provider if you have any history of infections. Tell your healthcare provider right away if you have signs or symptoms of an infection during treatment with VYVGART or VYVGART HYTRULO such as fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. If a serious infection occurs, your doctor will treat your infection and may even stop your VYVGART or VYVGART HYTRULO treatment until the infection has resolved.
- **Undesirable immune reactions (hypersensitivity reactions).** VYVGART and VYVGART HYTRULO can cause the immune system to have undesirable reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. In clinical studies, the reactions were mild or moderate and occurred within 1 hour to 3 weeks of administration, and the reactions did not lead to treatment discontinuation. Your healthcare provider should monitor you during and after treatment and discontinue VYVGART or VYVGART HYTRULO if needed. Tell your healthcare provider immediately about any undesirable reactions to VYVGART or VYVGART HYTRULO.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

- Have a history of infection or you think you have an infection.
- Have received or are scheduled to receive a vaccine (immunization). Discuss with your healthcare provider whether you need to receive age-appropriate immunizations before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO. The use of vaccines during treatment with VYVGART or VYVGART HYTRULO has not been studied, and the safety with live or live-attenuated vaccines is unknown. Administration of live or live-attenuated vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO.
- Are pregnant or plan to become pregnant and are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects of efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART for IV infusion and what is VYVGART HYTRULO for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for [VYVGART](#) and the full Prescribing Information for [VYVGART HYTRULO](#), and talk to your doctor.

Talk to your neurologist to see if VYVGART for IV infusion or VYVGART Hytrulo for subcutaneous injection is right for you

- ✓ When added to their current gMG treatment, VYVGART for IV infusion helped most patients in the study with anti-AChR antibody positive gMG achieve **improved daily abilities***
- ✓ VYVGART Hytrulo **was found to be effective** for adults with anti-AChR antibody positive gMG
- ✓ VYVGART for IV infusion and VYVGART Hytrulo for subcutaneous injection were **safe in treating most patients studied**

Want to know more about VYVGART for IV infusion?



Learn from a leading expert. Watch the webinar for an in-depth discussion on gMG and VYVGART for IV infusion at [VYVGARTWebinar.com](https://www.vyvgart.com/webinar).

*Improvement maintained for 4 or more weeks was measured by a decrease of 2 or more points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, with the first reduction occurring no later than 1 week after the last infusion of treatment cycle 1. The MG-ADL scale assesses the impact of gMG on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

AChR=acetylcholine receptor; gMG=generalized myasthenia gravis; IV=intravenous

Visit [VYVGART.com/glossary](https://www.vyvgart.com/glossary) for a glossary of terms.

SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

Please see Important Safety Information throughout. Please see full Prescribing Information for [VYVGART for IV infusion](#) and [VYVGART HYTRULO for subcutaneous injection](#).